{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T21:32:04Z","timestamp":1793914324535,"version":"4.8.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:00:00Z","timestamp":1780531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T00:00:00Z","timestamp":1785974400000},"content-version":"vor","delay-in-days":63,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the Science Foundation of Peking University Cancer Hospital","award":["BJCH2024CZ03"],"award-info":[{"award-number":["BJCH2024CZ03"]}]},{"DOI":"10.13039\/501100012166","name":"National Key R&D Program of China","doi-asserted-by":"crossref","award":["No. 2022YFC2406804"],"award-info":[{"award-number":["No. 2022YFC2406804"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"crossref"}]},{"name":"the Noncommunicable Chronic Diseases-National Science and Technology Major Project","award":["2023ZD0512400"],"award-info":[{"award-number":["2023ZD0512400"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Imaging"],"DOI":"10.1186\/s40644-026-01057-1","type":"journal-article","created":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T01:13:43Z","timestamp":1780535623000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Prognostic value of 18F-FDG PET\/CT metabolic parameters in patients with non\u2013small cell lung cancer who achieved a pathological complete response after neoadjuvant chemoimmunotherapy"],"prefix":"10.1186","volume":"26","author":[{"given":"Ye","family":"Tao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinrun","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaqi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoxuan","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zengjin","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,4]]},"reference":[{"key":"1057_CR1","first-page":"10","volume":"75","author":"RL Siegel","year":"2025","unstructured":"Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A. Cancer statistics, 2025. CA Cancer J Clin. 2025;75:10\u201345.","journal-title":"CA Cancer J Clin"},{"key":"1057_CR2","doi-asserted-by":"crossref","unstructured":"Forde PM, Spicer JD, Provencio M, Mitsudomi T, Awad MM, Wang C, et al. Overall survival with neoadjuvant nivolumab plus chemotherapy in lung cancer. N Engl J Med. 2025.","DOI":"10.1056\/NEJMoa2502931"},{"key":"1057_CR3","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1056\/NEJMoa2302983","volume":"389","author":"H Wakelee","year":"2023","unstructured":"Wakelee H, Liberman M, Kato T, Tsuboi M, Lee SH, Gao S, et al. Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer. N Engl J Med. 2023;389:491\u2013503.","journal-title":"N Engl J Med"},{"key":"1057_CR4","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1016\/j.jtho.2024.03.010","volume":"19","author":"JB Hines","year":"2024","unstructured":"Hines JB, Cameron RB, Esposito A, Kim L, Porcu L, Nuccio A, et al. Evaluation of Major Pathologic Response and Pathologic Complete Response as Surrogate End Points for Survival in Randomized Controlled Trials of Neoadjuvant Immune Checkpoint Blockade in Resectable in NSCLC. J Thorac Oncol. 2024;19:1108\u201316.","journal-title":"J Thorac Oncol"},{"key":"1057_CR5","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.jtho.2024.09.1443","volume":"20","author":"D Marinelli","year":"2025","unstructured":"Marinelli D, Nuccio A, Di Federico A, Ambrosi F, Bertoglio P, Faccioli E, et al. Improved Event-Free Survival After Complete or Major Pathologic Response in Patients With Resectable NSCLC Treated With Neoadjuvant Chemoimmunotherapy Regardless of Adjuvant Treatment: A Systematic Review and Individual Patient Data Meta-Analysis. J Thorac Oncol. 2025;20:285\u201395.","journal-title":"J Thorac Oncol"},{"key":"1057_CR6","doi-asserted-by":"crossref","unstructured":"Yang Z, Wang S, Yang H, Jiang Y, Zhu L, Zheng B, et al. Treatment patterns and clinical outcomes of patients with resectable non-small cell lung cancer receiving neoadjuvant immunochemotherapy: a large-scale, multicenter, real-world study (NeoR-World). J Thorac Cardiovasc Surg. 2024;168:1245-58.e17.","DOI":"10.1016\/j.jtcvs.2024.02.006"},{"key":"1057_CR7","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s40644-024-00772-x","volume":"24","author":"R Guo","year":"2024","unstructured":"Guo R, Yan W, Wang F, Su H, Meng X, Xie Q, et al. The utility of 18F-FDG PET\/CT for predicting the pathological response and prognosis to neoadjuvant immunochemotherapy in resectable non-small-cell lung cancer. Cancer Imaging. 2024;24:120.","journal-title":"Cancer Imaging"},{"key":"1057_CR8","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1186\/s12885-025-13905-7","volume":"25","author":"X Liu","year":"2025","unstructured":"Liu X, Ji Z, Zhang L, Li L, Xu W, Su Q. Prediction of pathological complete response to neoadjuvant chemoimmunotherapy in non-small cell lung cancer using (18)F-FDG PET radiomics features of primary tumour and lymph nodes. BMC Cancer. 2025;25:520.","journal-title":"BMC Cancer"},{"key":"1057_CR9","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1097\/RLU.0000000000005910","volume":"50","author":"X Tao","year":"2025","unstructured":"Tao X, Zhang Q, Li N, Wang S, Guo W, Yuan P, et al. Prognostic Value of 18F-FDG PET\/CT in Neoadjuvant PD-1 Inhibitor-treated NSCLC: A Five-year Follow-up Study. Clin Nucl Med. 2025;50:577\u201387.","journal-title":"Clin Nucl Med"},{"key":"1057_CR10","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1186\/s40644-024-00811-7","volume":"24","author":"A Brose","year":"2024","unstructured":"Brose A, Miederer I, K\u00f6nig J, Gkika E, Sahlmann J, Schimek-Jasch T, et al. Prognostic value of metabolic tumor volume on [(18)F]FDG PET\/CT in addition to the TNM classification system of locally advanced non-small cell lung cancer. Cancer Imaging. 2024;24:171.","journal-title":"Cancer Imaging"},{"key":"1057_CR11","doi-asserted-by":"crossref","unstructured":"Kwon W, Howard BA, Herndon JE, Patz EF, Jr. FDG uptake on positron emission tomography correlates with survival and time to recurrence in patients with stage I Non\u2013Small-Cell Lung Cancer. J Thorac Oncol. 2015;10:897\u2013902.","DOI":"10.1097\/JTO.0000000000000534"},{"key":"1057_CR12","doi-asserted-by":"publisher","first-page":"109728","DOI":"10.1016\/j.radonc.2023.109728","volume":"185","author":"B Grambozov","year":"2023","unstructured":"Grambozov B, Kalantari F, Beheshti M, Stana M, Karner J, Ruznic E, et al. Pretreatment 18-FDG-PET\/CT parameters can serve as prognostic imaging biomarkers in recurrent NSCLC patients treated with reirradiation-chemoimmunotherapy. Radiother Oncol. 2023;185:109728.","journal-title":"Radiother Oncol"},{"key":"1057_CR13","first-page":"100384","volume":"3","author":"S Rosner","year":"2022","unstructured":"Rosner S, Liu C, Forde PM, Hu C. Association of Pathologic Complete Response and Long-Term Survival Outcomes Among Patients Treated With Neoadjuvant Chemotherapy or Chemoradiotherapy for NSCLC: A Meta-Analysis. JTO Clin Res Rep. 2022;3:100384.","journal-title":"JTO Clin Res Rep"},{"key":"1057_CR14","doi-asserted-by":"publisher","first-page":"e42","DOI":"10.1016\/S1470-2045(13)70334-6","volume":"15","author":"MD Hellmann","year":"2014","unstructured":"Hellmann MD, Chaft JE, William WN Jr., Rusch V, Pisters KM, Kalhor N, et al. Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint. Lancet Oncol. 2014;15:e42\u201350.","journal-title":"Lancet Oncol"},{"key":"1057_CR15","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.21037\/jtd-2024-2200","volume":"17","author":"Y Fang","year":"2025","unstructured":"Fang Y, Yan W, Zhao ZR, Jiang L, Yu X, Yang X, et al. Prognosis and relapse patterns in patients with non-small cell lung cancer with pathologic complete response after neoadjuvant immunochemotherapy. J Thorac Dis. 2025;17:2113\u201325.","journal-title":"J Thorac Dis"},{"key":"1057_CR16","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1097\/RLU.0000000000000867","volume":"40","author":"DH Kim","year":"2015","unstructured":"Kim DH, Jung JH, Son SH, Kim CY, Hong CM, Oh JR, et al. Prognostic Significance of Intratumoral Metabolic Heterogeneity on 18F-FDG PET\/CT in Pathological N0 Non-Small Cell Lung Cancer. Clin Nucl Med. 2015;40:708\u201314.","journal-title":"Clin Nucl Med"},{"key":"1057_CR17","doi-asserted-by":"crossref","unstructured":"Lei B, Zhang H, Sun J, Wang L, Ruan M, Yan H, et al. The potential of basal F-18-FDG PET\/CT in evaluating prognosis and benefit from adjuvant chemotherapy after tumor resection of stage IB(T2, \u2264 3\u00a0cm With VPI, N0, M0)NSCLC. Clin Lung Cancer. 2024.","DOI":"10.1016\/j.cllc.2024.11.001"},{"key":"1057_CR18","doi-asserted-by":"publisher","first-page":"821","DOI":"10.2967\/jnumed.119.237768","volume":"61","author":"A Castello","year":"2020","unstructured":"Castello A, Rossi S, Mazziotti E, Toschi L, Lopci E. Hyperprogressive Disease in Patients with Non-Small Cell Lung Cancer Treated with Checkpoint Inhibitors: The Role of (18)F-FDG PET\/CT. J Nucl Med. 2020;61:821\u201326.","journal-title":"J Nucl Med"},{"key":"1057_CR19","doi-asserted-by":"publisher","first-page":"4083","DOI":"10.1007\/s00259-024-06819-2","volume":"51","author":"D Wang","year":"2024","unstructured":"Wang D, Mo Y, Liu F, Zheng S, Liu H, Li H, et al. Repeated dynamic [(18)F]FDG PET\/CT imaging using a high-sensitivity PET\/CT scanner for assessing non-small cell lung cancer patients undergoing induction immuno-chemotherapy followed by hypo-fractionated chemoradiotherapy and consolidative immunotherapy: report from a prospective observational study (GASTO-1067). Eur J Nucl Med Mol Imaging. 2024;51:4083\u201398.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1057_CR20","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.cllc.2021.03.001","volume":"22","author":"K Vekens","year":"2021","unstructured":"Vekens K, Everaert H, Neyns B, Ilsen B, Decoster L. The Value of (18)F-FDG PET\/CT in Predicting the Response to PD-1 Blocking Immunotherapy in Advanced NSCLC Patients with High-Level PD-L1 Expression. Clin Lung Cancer. 2021;22:432\u201340.","journal-title":"Clin Lung Cancer"},{"key":"1057_CR21","doi-asserted-by":"publisher","first-page":"175883592412933","DOI":"10.1177\/17588359241293364","volume":"16","author":"M Huang","year":"2024","unstructured":"Huang M, Zou Y, Wang W, Li Q, Tian R. The role of baseline (18)F-FDG PET\/CT for survival prognosis in NSCLC patients undergoing immunotherapy: a systematic review and meta-analysis. Ther Adv Med Oncol. 2024;16:17588359241293364.","journal-title":"Ther Adv Med Oncol"},{"key":"1057_CR22","doi-asserted-by":"crossref","unstructured":"Wang C, Wang C, Zhang J, Ding M, Ge Y, He X. Development and validation of a radiogenomics prognostic model integrating PET\/CT radiomics and glucose metabolism-related gene signatures for non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 2025.","DOI":"10.1007\/s00259-025-07354-4"},{"key":"1057_CR23","doi-asserted-by":"crossref","unstructured":"Zhuang M, Garc\u00eda DV, Kramer GM, Frings V, Smit EF, Dierckx R, et al. Variability and repeatability of quantitative uptake Metrics in 18F-FDG PET\/CT of Non\u2013Small Cell Lung Cancer: Impact of Segmentation Method, Uptake Interval,and Reconstruction Protocol. Journal of Nuclear Medicine. 2019;60:600.","DOI":"10.2967\/jnumed.118.216028"},{"key":"1057_CR24","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.lungcan.2019.06.009","volume":"134","author":"N Kasahara","year":"2019","unstructured":"Kasahara N, Kaira K, Yamaguchi K, Masubuchi H, Tsurumaki H, Hara K, et al. Fluorodeoxyglucose uptake is associated with low tumor-infiltrating lymphocyte levels in patients with small cell lung cancer. Lung Cancer. 2019;134:180\u201386.","journal-title":"Lung Cancer"},{"key":"1057_CR25","doi-asserted-by":"publisher","first-page":"101725","DOI":"10.1016\/j.tranon.2023.101725","volume":"35","author":"X Chen","year":"2023","unstructured":"Chen X, Bai G, Zang R, Song P, Bie F, Huai Q, et al. Utility of (18)F-FDG uptake in predicting major pathological response to neoadjuvant immunotherapy in patients with resectable non\u2013small cell lung cancer. Transl Oncol. 2023;35:101725.","journal-title":"Transl Oncol"},{"key":"1057_CR26","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1007\/s00259-020-04711-3","volume":"47","author":"X Tao","year":"2020","unstructured":"Tao X, Li N, Wu N, He J, Ying J, Gao S, et al. The efficiency of (18)F-FDG PET-CT for predicting the major pathologic response to the neoadjuvant PD-1 blockade in resectable non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 2020;47:1209\u201319.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1057_CR27","doi-asserted-by":"publisher","first-page":"4352","DOI":"10.1007\/s00330-023-10503-8","volume":"34","author":"M Yang","year":"2024","unstructured":"Yang M, Li X, Cai C, Liu C, Ma M, Qu W, et al. [(18)F]FDG PET-CT radiomics signature to predict pathological complete response to neoadjuvant chemoimmunotherapy in non-small cell lung cancer: a multicenter study. Eur Radiol. 2024;34:4352\u201363.","journal-title":"Eur Radiol"},{"key":"1057_CR28","doi-asserted-by":"publisher","first-page":"e344","DOI":"10.1097\/RLU.0000000000005863","volume":"50","author":"Y Cheng","year":"2025","unstructured":"Cheng Y, Jiang ZP, Chen XB, Lu KY, Liu ZY, Shao D. Prognostic Value of 18 F-FDG PET\/CT Metabolic Parameters in Resectable Non-small Cell Lung Cancer Treated With Neoadjuvant Immunotherapy Plus Chemotherapy. Clin Nucl Med. 2025;50:e344\u201351.","journal-title":"Clin Nucl Med"},{"key":"1057_CR29","doi-asserted-by":"crossref","unstructured":"Rahim MK, Okholm TLH, Jones KB, McCarthy EE, Liu CC, Yee JL, et al. Dynamic CD8(+) T cell responses to cancer immunotherapy in human regional lymph nodes are disrupted in metastatic lymph nodes. Cell. 2023;186:1127-43.e18.","DOI":"10.1016\/j.cell.2023.02.021"},{"key":"1057_CR30","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s40164-023-00401-6","volume":"12","author":"H Deng","year":"2023","unstructured":"Deng H, Xiong S, Zhong R, Zheng Y, Liang H, Cheng B. Major pathologic response in lymph nodes: a modified nodal classification for non-small cell lung cancer patients treated with neoadjuvant immunochemotherapy. Exp Hematol Oncol. 2023;12:40.","journal-title":"Exp Hematol Oncol"},{"key":"1057_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.humpath.2024.05.009","volume":"149","author":"W Sun","year":"2024","unstructured":"Sun W, Qu L, Wu J, Liu X, Wang C, Jiang Y, et al. Percentage and size of residual viable tumor in lymph node, the performance in estimating pathologic response of lymph node in non-small cell lung cancer treated with neoadjuvant chemoimmunotherapy. Hum Pathol. 2024;149:1\u20139.","journal-title":"Hum Pathol"},{"key":"1057_CR32","doi-asserted-by":"publisher","first-page":"8564","DOI":"10.1007\/s00330-023-09910-8","volume":"33","author":"L Zhang","year":"2023","unstructured":"Zhang L, Huang EH, Wu J, Li J, Hou Q. Clinical utility of [(18)F]FDG PET\/CT in the assessment of mediastinal lymph node disease after neoadjuvant chemoimmunotherapy for non-small cell lung cancer. Eur Radiol. 2023;33:8564\u201372.","journal-title":"Eur Radiol"},{"key":"1057_CR33","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.cllc.2019.07.004","volume":"21","author":"A Castello","year":"2020","unstructured":"Castello A, Toschi L, Rossi S, Finocchiaro G, Grizzi F, Mazziotti E, et al. Predictive and Prognostic Role of Metabolic Response in Patients With Stage III NSCLC Treated With Neoadjuvant Chemotherapy. Clin Lung Cancer. 2020;21:28\u201336.","journal-title":"Clin Lung Cancer"},{"key":"1057_CR34","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1016\/j.jtho.2024.09.014","volume":"19","author":"PM Forde","year":"2024","unstructured":"Forde PM, Peters S, Donington J, Meadows-Shropshire S, Tran P, Lucherini S, et al. PL02.08 Perioperative vs Neoadjuvant Nivolumab for Resectable NSCLC: Patient-Level Data Analysis of CheckMate 77T vs CheckMate 816. J Thorac Oncol. 2024;19:S2.","journal-title":"J Thorac Oncol"},{"key":"1057_CR35","unstructured":"Zhao ZR, Yan WP, Yu XY, Zhang JB, Fang YF, Ma K, et al. Adjuvant immunotherapy does not improve survival in non-small cell lung cancer with major\/complete pathologic response after induction immunotherapy. J Thorac Cardiovasc Surg; 2024."}],"container-title":["Cancer Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40644-026-01057-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40644-026-01057-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40644-026-01057-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T10:11:26Z","timestamp":1786011086000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40644-026-01057-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,4]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1057"],"URL":"https:\/\/doi.org\/10.1186\/s40644-026-01057-1","relation":{},"ISSN":["1470-7330"],"issn-type":[{"value":"1470-7330","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,4]]},"assertion":[{"value":"4 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki. The study protocol was reviewed and approved by the Ethics Committee of Peking University Cancer Hospital (Approval No. 2024KT92). Informed consent was obtained from the patients prospectively as they underwent surgical resection.","order":1,"name":"Ethics","label":"Ethics statement and consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"99"}}